- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01326871
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
A Phase Ib/II Trial of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Bladder cancer is the fourth most common malignancy in men and the ninth most common in women in the US, with an estimated 68,810 new cases and 14,070 deaths for the year 2008. Approximately 90% to 95% of newly diagnosed patients are with transitional cell carcinomas (TCC). Approximately 20% to 25% contain advanced (muscle invasive or metastatic) disease. Muscle invasive bladder cancer is life threatening. Clinical trials have demonstrated that TCC is a chemotherapy-sensitive malignancy. Most current cancer treatment strategies involve the use of chemotherapeutic or biological drugs that have a low therapeutic ratio. The limitations are a consequence of effects of the therapeutic drug on normal tissues. One approach to control systemic exposure effects is to target the drug itself into the site of the tumor. For example, antibodies have been developed for use as tumor targeting agents and have had success in the clinic. However, despite the promise of antibody-based immunotherapy, there are limitations with these class of reagents. Even so, immunotherapy remains a promising approach to treat cancer.
One strategy that has received attention is treatment with cytokines such as IL-2 to enhance anti-tumor immunity. IL-2 has stimulatory effects on a number of immune cell types including T and B cells, monocytes, macrophages, lymphokine-activated killer cells (LAK) and natural killer (NK) cells. Based on the ability of IL-2 to provide durable curative anti-tumor responses, systemic administration of IL-2 has been approved to treat patients with metastatic melanoma or renal carcinoma. Unfortunately, the considerable toxicity associated with this treatment makes it difficult to achieve an effective dose at the site of the tumor and limits the population that can be treated. Thus, there is critical need for innovative strategies that enhance the effects of IL-2, to reduce its toxicity without compromising the clinical benefit, and to treat other diagnoses.
The study drug, ALT-801, is a biologic compound of interleukin-2 (IL-2) genetically fused to a humanized soluble T-cell receptor directed against the p53-derived peptides expressed on tumor cells. The p53 protein is one of the most important factors that protects from developing cancer and is also one of the most frequently mutated genes in many cancers, which include muscle-invasive bladder cancer. For any given cancer type, p53 dysfunction generally correlates with poor prognosis versus other the same site-of-origin. In some tumors, p53 mutation and over-expression also is associated with resistance to chemotherapy. This study is to further evaluate whether directing IL-2 activity using ALT-801 to the patient's tumor sites that over-express p53 results in clinical benefits
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Arizona
-
Tucson, Arizona, United States, 85724
- The University of Arizona Cancer Center
-
-
Florida
-
Orlando, Florida, United States, 32806
- UF Health Center at Orlando Health
-
Stuart, Florida, United States, 34994
- Martin Health System
-
Tampa, Florida, United States, 33612
- H. Lee Moffitt Cancer Center and Research Institute
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Robert Lurie Comprehensive Cancer Center of Northwestern University
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa Hospitals and Clinics
-
-
Kansas
-
Fairway, Kansas, United States, 66205
- University of Kansas Cancer Center
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Karmanos Cancer Center
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota
-
-
Missouri
-
St. Louis, Missouri, United States, 63110
- Washington University
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28203
- Levine Cancer Institute
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- University of Oklahoma Health Science Center
-
-
Pennsylvania
-
Easton, Pennsylvania, United States, 18045
- St. Luke's Hospital and Health Network
-
Philadelphia, Pennsylvania, United States, 19107
- Thomas Jefferson University Hospital
-
Pittsburgh, Pennsylvania, United States, 15232
- UPMC Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
ENTRY CRITERIA:
DISEASE CHARATERISTICS:
- Muscle invasive or metastatic urothelial cancer of bladder, ureters, renal pelvis, and urethra
Histologically or cytologically confirmed with a clinical plan that would potentially include cisplatin* plus gemcitabine systemic therapy or with disease refractory to a first-line platinum-based therapy (as defined in the protocol).
* Does not apply to patients screened for Phase II expansion
- Surgically incurable
PRIOR/CONCURRENT THERAPY:
- No concurrent radiotherapy, other chemotherapy, or other immunotherapy
- Must have recovered from side effects of prior treatments
- If prior Proleukin® treatment, must have had a clinical benefit
- No use of other investigational agents within 30 days of start or concurrently
PATIENT CHARACTERISTICS:
Age
- ≥ 18 years
Performance Status
- ECOG 0 or 1
Bone Marrow Reserve
- Absolute neutrophil count (AGC/ANC) ≥ 1,500/uL
- Platelets ≥ 100,000/uL
- Hemoglobin ≥ 10g/dL
Renal Function
Glomerular Filtration Rate (GFR):
- ≥ 50mL/min/1.73m^2 for cisplatin-containing regimen
- ≥ 40mL/min/1.73m^2 for non-cisplatin-containing regimen
Hepatic Function
- Total bilirubin ≤ 1.5 X ULN
- AST, ALT, ALP ≤ 2.5 X ULN, or ≤ 5.0 X ULN (if liver metastases exists)
- PT INR ≤ 1.5 X ULN
Cardiovascular
- No congestive heart failure < 6 months
- No unstable angina pectoris < 6 months
- No myocardial infarction < 6 months
- No history of ventricular arrhythmias
- No NYHA Class > II CHF
- Normal cardiac stress test required for subjects who are ≥ 50 years old, or have a history of EKG abnormalities, or have symptoms of cardiac ischemia or arrhythmia
- No uncontrolled hypertension
Pulmonary
- Not receiving chronic medication for asthma
- Normal clinical assessment of pulmonary function
Hematologic
- No evidence of bleeding diathesis or coagulopathy
Other
- Negative serum pregnancy test if female and of childbearing potential
- No women who are pregnant or nursing
- Subjects, both females and males, with reproductive potential must agree to use effective contraceptive measures for the duration of the study
- No known autoimmune disease other than corrected hypothyroidism
- No known prior organ allograft or allogeneic transplantation
- Not HIV positive
- No active systemic infection requiring parenteral antibiotic therapy
- No ongoing systemic steroid therapy required
- No history or evidence of CNS disease (Controlled brain metastases treated with radiation therapy or surgery where the disease has been clinically stable for a period of a least 3 months before screening is allowed)
- No psychiatric illness/social situation
- No other illness that in the opinion of the investigator would exclude the subject from participating in the study
- Must provide informed consent and HIPAA authorization and agree to comply with all protocol-specified procedures and follow-up evaluations
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ALT-801 with Cisplatin and Gemcitabine (Phase Ib and Phase II)
|
Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II): on day 1 of each course (if given)
Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II); on day 1 and 8 of each course
Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II): on day 3, 5, 8, and 12 of each course
Other Names:
|
Experimental: ALT-801 and Gemcitabine (Phase II only)
|
Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II); on day 1 and 8 of each course
Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II): on day 3, 5, 8, and 12 of each course
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose (MTD) and/or the recommended dose (RD) for dose expansion of ALT-801 in combination with cisplatin and gemcitabine or ALT-801 in combination with gemcitabine alone
Time Frame: 8 weeks
|
8 weeks
|
|
Safety Profile
Time Frame: 8 weeks
|
Number and severity of treatment related AEs that occur or worsen after the first dose of study treatment
|
8 weeks
|
Clinical Benefit
Time Frame: 12 weeks
|
Number of participants with an objective response, which includes, a complete response,a partial response or a stable disease
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression Free Survival
Time Frame: 36 months
|
Number of participants with, 6-month, 9-month, 12-month, 18-month, 24-month, 30-month, or 36-month progression-free survival.
|
36 months
|
Overall survival
Time Frame: 36 months
|
Number of participants with 6-month, 9-month, 12-month, 18-month, 24-month, 30-month or 36-month overall survival
|
36 months
|
Pharmacokinetics and immunogenicity
Time Frame: 9 weeks
|
Area under the plasma concentration-time curve from time zero to infinity (AUC) and the half-life of ALT-801 for patients enrolled up to the stage 1 expansion. Measures of anti-ALT-801 and IL-2 neutralizing antibodies |
9 weeks
|
Tumor Typing
Time Frame: 1 month
|
Assess the relationship between the tumor presentation of HLA-A*0201/p53 aa 264-272 complexes and the safety and clinical benefits of study treatment
|
1 month
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Hing C Wong, PhD, Altor BioScience
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- cisplatin
- immunotherapy
- cancer
- bladder cancer
- immunochemotherapy
- urothelial cancer
- combinational therapy
- targeted
- metastatic
- muscle invasive
- interleukin-2
- gemcitabine
- antitumor
- TCR
- T-cell receptor
- p53
- p53 gene
- p53 tumor supressor protein
- renal pelvis cancer
- ureters cancer
- urethra cancer
- HLA-A2 positive
- HLA-A*0201/p53 aa264-272
- HLA complex
- Muscle Invasive or Metastatic
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Urologic Diseases
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Urinary Bladder Diseases
- Ureteral Diseases
- Urethral Diseases
- Neoplasms
- Urinary Bladder Neoplasms
- Carcinoma, Transitional Cell
- Ureteral Neoplasms
- Urethral Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Gemcitabine
- Cisplatin
Other Study ID Numbers
- CA-ALT-801-01-10
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Transitional Cell Carcinoma of Bladder
-
Anchiano Therapeutics Israel Ltd.CompletedTransitional Cell Carcinoma of BladderIsrael
-
Lipac Oncology LLCTesoRx Pharma, LLCCompletedUrologic Neoplasms | Urogenital Neoplasms | Urologic Diseases | Urinary Bladder Diseases | Urinary Bladder Neoplasms | Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Non-Muscle Invasive Bladder Cancer | Urinary Bladder | Bladder Cancer Cell TransitionalUnited States
-
Trans Tasman Radiation Oncology GroupNational Health and Medical Research Council, AustraliaCompletedTransitional Cell Carcinoma of Urinary BladderAustralia, New Zealand
-
Noah Hahn, M.D.Pfizer; Hoosier Cancer Research NetworkTerminatedTransitional Cell Carcinoma of the BladderUnited States, United Kingdom
-
Hoosier Cancer Research NetworkBristol-Myers SquibbCompletedTransitional Cell Carcinoma of the BladderUnited States
-
National Cancer Institute (NCI)CompletedMetastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Squamous Cell Carcinoma of the BladderUnited States
-
Emory UniversityTerminatedBladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Squamous Cell Carcinoma of the BladderUnited States
-
National Cancer Institute (NCI)CompletedMetastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Regional Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional...Canada
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...CompletedTransitional Cell Carcinoma of BladderItaly
-
Erasmus Medical CenterMerck Sharp & Dohme LLCActive, not recruitingBiomarkers | Transitional Cell Carcinoma of the BladderNetherlands
Clinical Trials on Cisplatin
-
West China Second University HospitalRecruitingNeoadjuvant Chemotherapy | Epithelial Carcinoma, OvarianChina
-
Insmed IncorporatedCompletedOsteosarcoma MetastaticUnited States
-
Privo TechnologiesNational Cancer Institute (NCI)CompletedOral Squamous Cell CarcinomaUnited States
-
Samsung Medical CenterUnknownNasophayngeal Carcinoma Between Stage II and IVbKorea, Republic of
-
Cedars-Sinai Medical CenterRecruitingHPV Positive Oropharyngeal Squamous Cell CarcinomaUnited States
-
Korea Cancer Center HospitalCompletedCervical CancersKorea, Republic of
-
Taiho Oncology, Inc.Quintiles, Inc.Completed
-
Sun Yat-sen UniversityActive, not recruitingNasopharyngeal CarcinomaChina
-
Lawson Health Research InstituteRecruitingLocally Advanced Head and Neck Squamous Cell CarcinomaCanada
-
Sun Yat-sen UniversityFirst Affiliated Hospital, Sun Yat-Sen University; Guangdong Provincial People... and other collaboratorsActive, not recruitingNasopharyngeal Carcinoma | Nasopharyngeal Neoplasms | Nasopharyngeal Diseases | Head and Neck NeoplasmChina